Paco E Bravo1, Sharmila Dorbala2. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, the Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiology) and Radiology, Cardiac Amyloidosis Program, Department of Medicine, Brigham and Women's Hospital, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA, 02115, USA. 2. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, the Noninvasive Cardiovascular Imaging Program, Departments of Medicine (Cardiology) and Radiology, Cardiac Amyloidosis Program, Department of Medicine, Brigham and Women's Hospital, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA, 02115, USA. sdorbala@partners.org.
Abstract
PURPOSE OF REVIEW: The aim of the present manuscript is to review the latest advancements of radionuclide molecular imaging in the diagnosis and prognosis of individuals with cardiac amyloidosis. RECENT FINDINGS: 99mTechnetium labeled bone tracer scintigraphy had been known to image cardiac amyloidosis, since the 1980s; over the past decade, bone scintigraphy has been revived specifically to diagnose transthyretin cardiac amyloidosis. 18F labeled and 11C labeled amyloid binding radiotracers developed for imaging Alzheimer's disease, have been repurposed since 2013, to image light chain and transthyretin cardiac amyloidosis. 99mTechnetium bone scintigraphy for transthyretin cardiac amyloidosis, and amyloid binding targeted PET imaging for light chain and transthyretin cardiac amyloidosis, are emerging as highly accurate methods. Targeted radionuclide imaging may soon replace endomyocardial biopsy in the evaluation of patients with suspected cardiac amyloidosis. Further research is warranted on the role of targeted imaging to quantify cardiac amyloidosis and to guide therapy.
PURPOSE OF REVIEW: The aim of the present manuscript is to review the latest advancements of radionuclide molecular imaging in the diagnosis and prognosis of individuals with cardiac amyloidosis. RECENT FINDINGS:99mTechnetium labeled bone tracer scintigraphy had been known to image cardiac amyloidosis, since the 1980s; over the past decade, bone scintigraphy has been revived specifically to diagnose transthyretincardiac amyloidosis. 18F labeled and 11C labeled amyloid binding radiotracers developed for imaging Alzheimer's disease, have been repurposed since 2013, to image light chain and transthyretincardiac amyloidosis. 99mTechnetium bone scintigraphy for transthyretincardiac amyloidosis, and amyloid binding targeted PET imaging for light chain and transthyretincardiac amyloidosis, are emerging as highly accurate methods. Targeted radionuclide imaging may soon replace endomyocardial biopsy in the evaluation of patients with suspected cardiac amyloidosis. Further research is warranted on the role of targeted imaging to quantify cardiac amyloidosis and to guide therapy.
Authors: Mi-Ae Park; Robert F Padera; Anthony Belanger; Shipra Dubey; David H Hwang; Vikas Veeranna; Rodney H Falk; Marcelo F Di Carli; Sharmila Dorbala Journal: Circ Cardiovasc Imaging Date: 2015-08 Impact factor: 7.792
Authors: Richard L Wahl; Panithaya Chareonthaitawee; Bonnie Clarke; Alexander Drzezga; Liza Lindenberg; Arman Rahmim; James Thackeray; Gary A Ulaner; Wolfgang Weber; Katherine Zukotynski; John Sunderland Journal: J Nucl Med Date: 2021-01 Impact factor: 11.082
Authors: Rudolf A Werner; James T Thackeray; Johanna Diekmann; Desiree Weiberg; Johann Bauersachs; Frank M Bengel Journal: J Nucl Med Date: 2020-04-17 Impact factor: 11.082
Authors: Ali M Agha; Purvi Parwani; Avirup Guha; Jean B Durand; Cezar A Iliescu; Saamir Hassan; Nicolas L Palaskas; Greg Gladish; Peter Y Kim; Juan Lopez-Mattei Journal: Open Heart Date: 2018-09-26